General Archive
-
News releases
MRCT and Biolex Therapeutics complete successful collaborations
MRCT has successfully completed the humanization of a novel antibody targeting CD20, indicated in Non-Hodgkin’s lymphoma and rheumatoid arthritis. Biolex…
-
News releases
Intellect Neurosciences and MRCT reach antibody milestone
The milestone is an important stage in the collaborative efforts to humanize Intellect’s lead antibody IN-N01 necessary for creating a…
-
News releases
Development Gap Fund extended
The MRC has approved a further £6 million of funding for a continuation of the MRCT Development Gap Fund (DGF).…
-
News releases
How malaria parasites escape blood cells
a collaboration between teams at the MRC’s National Institute for Medical Research and MRCT’s Drug Discovery Group has produced a…
-
News releases
Intellect Neurosciences and MRCT to humanize antibodies for AD
MRCT will use its proprietary technology and advanced know-how to humanize Intellect’s beta-amyloid specific, monoclonal antibodies for the treatment of…
-
News releases
Organon and MRC Technology sign antibody development agreement
The collaborative agreement will cover development of a humanised antibody for the treatment of certain forms of cancer. The Therapeutic…
-
News releases
MRCT to humanize antibody to treat SLE
SLE is a very important disease area, affecting over 1.5 Million people in the USA without any effective therapies. MRCT…
-
News releases
MRCT to humanize antibody to treat AD
MRC Technologyand BioArctic Neuroscience have signed an collaborative research agreement to humanise a mouse antibody under development with BioArctic for…
-
News releases
Domantis wins award
Domantis, a spin-out company from the MRC, is the first to win the UK Innovation in Drug Discovery & Development…
-
News releases
TYSABRI gains market approval
Biogen Idec and Elan Corporation yesterday announced the approval of a supplemental Biologics License Application (sBLA) by the U.S. Food…
-
News releasesMRCT and Chinese National Centre collaborate on malaria
MRCT’s Drug Discovery Group has developed a drug screening assay for a potential Malaria drug target called PfSub-1, a subtilisin-like…
-
News releasesTherapeutic Antibody Group starts
The Therapeutic Antibody Group (TAG) will comprise former AERES scientists. As part of MRCT’s evolving strategy of adding significant value…